Sign In
Buy AMGN
$345.60
+7.38 (+2.18%)
At Close: Jun 04, 2026
Final Trades: Intuit, Amgen, the INDY and URNM
01:51pm, Wednesday, 28'th Aug 2024
The Investment Committee give you their top stocks to watch for the second half.
Amgen: Growth Is Still A Better Choice
11:48am, Wednesday, 28'th Aug 2024
On August 6, Amgen released financial results for the second quarter of 2024, which pleasantly shocked me thanks to strong sales of its oncology and rheumatology franchises. So, Evenity sales reached
Obesity drugs' next wave: These companies could snag 20% of GLP-1 market, analysts say
12:00pm, Monday, 26'th Aug 2024
While Eli Lilly & Co. and Novo Nordisk dominate the obesity-drug market, there's a vast field of would-be competitors closing in behind them — and the most successful among those next-wave contender
Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know
10:01am, Monday, 26'th Aug 2024
Zacks.com users have recently been watching Amgen (AMGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
3 Unstoppable Dividend Stocks to Buy Right Now
06:30pm, Sunday, 25'th Aug 2024
Abbott Laboratories is a Dividend King with a diverse business. Amgen offers a high dividend yield plus a track record of innovation.
OTEZLA® (APREMILAST) NOW AVAILABLE IN THE U.S. FOR MODERATE TO SEVERE PEDIATRIC PLAQUE PSORIASIS
09:00am, Tuesday, 20'th Aug 2024
First and Only Pill for Children and Adolescents Ages 6-17 with Moderate to Severe Plaque Psoriasis THOUSAND OAKS, Calif. , Aug. 20, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced Otezla® (
2 Dow Jones Dividend Stocks With Above-Average Yields to Buy Now and Hold for at Least a Decade
05:25am, Sunday, 18'th Aug 2024
The Dow Jones Industrial Average contains shares of 30 companies that lead their respective industries. Now that it no longer sells consumer goods, Johnson & Johnson's dividend growth rate could shift
This Healthcare Giant Had 12 Products That Generated Double-Digit Growth Last Quarter and There's Still Many More in the Pipeline
06:20am, Saturday, 17'th Aug 2024
Amgen generated 20% revenue growth in its most recent quarter. The business has several fast-growing drugs showing double-digit growth despite generating over $200 million in quarterly sales.
3 ‘Recession-Resistant' Dividends Growing Up To 12% Annually
10:39am, Thursday, 15'th Aug 2024
Let's talk about recession-resistant dividends because, if history is any guide, we are certainly “on the clock” for a slowdown if not already in one. Here at Contrarian Outlook we have been prepa
Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It
10:00am, Tuesday, 13'th Aug 2024
Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Amgen: Q2 Earnings Review: Still Solid, But Wait For MariTide Data Goes On
02:18pm, Friday, 09'th Aug 2024
Amgen Inc., the Thousand Oaks headquartered Pharma giant, reported its Q2 2024 earnings on August 6th. My last coverage of Amgen was in May after Q1 earnings, and I awarded the stock a “buy” recom
Building A $100,000 Dividend Portfolio With 3 ETFs And 3 Stocks
12:15pm, Friday, 09'th Aug 2024
Times of higher uncertainty and elevated market volatility can provide investors with excellent opportunities to start building a dividend portfolio. The dividend portfolio I will present in today's a
Amgen Stock Slides on Lowered Guidance
07:21pm, Wednesday, 07'th Aug 2024
Amgen (AMGN) shares tumbled 5% Wednesday after the drug developer lowered its full-year earnings guidance.
Amgen's Mixed Q2 Results Highlight Obesity Drug Potential, Analysts Focus Shifts To Upcoming Clinical Readouts
02:01pm, Wednesday, 07'th Aug 2024
On Tuesday, Amgen Inc. AMGN reported mixed second-quarter results.
Why Amgen Stock Is Down Today Despite Solid Q2 Results
01:11pm, Wednesday, 07'th Aug 2024
The pharmaceutical company's second-quarter numbers were roughly in line with expectations. Amgen's slight earnings miss, however, was enough to spark a sizeable sell-off.
